Pevion Biotech Ltd – Product Pipeline Review – Q1
2011
Reference Code: GMDHC0637CDB
Publication Date: MAR 2011
Pevion Biotech Ltd – Product Pipeline Review – Q1 2011 GMDHC0637CDB / Published MAR 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Pevion Biotech Ltd – Product Pipeline Review
Ta b le o f Co n te n ts
Table of Contents 2
List of Tables 4
List of Figures 4
Pevion Biotech Ltd Snapshot 5
Pevion Biotech Ltd Overview 5
Key Information 5
Key Facts 5
Pevion Biotech Ltd – Research and Development Overview 6
Key Therapeutic Areas 6
Pevion Biotech Ltd – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Pevion Biotech Ltd – Pipeline Products Glance 10
Pevion Biotech Ltd Clinical Stage Pipeline Products 10
Phase I Products/Combination Treatment Modalities 10
Pevion Biotech Ltd–Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Pevion Biotech Ltd – Drug Profiles 12
HCV Vaccine 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
PEV6 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
PEV7 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Virosome-Based Breast Cancer Vaccine 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
PEV4 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
PEV8 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
RSV Vaccine 18
Product Description 18
R&D Progress 18
Pevion Biotech Ltd – Pipeline Analysis 19
Pevion Biotech Ltd – Product Pipeline Review – Q1 2011 GMDHC0637CDB / Published MAR 2011
©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(2)
Pevion Biotech Ltd – Product Pipeline Review
Pevion Biotech Ltd – Pipeline Products by Therapeutic Class 19
Pevion Biotech Ltd - Pipeline Products By Target 20
Pevion Biotech Ltd – Pipeline Products by Route of Administration 21
Pevion Biotech Ltd – Pipeline Products by Molecule Type 22
Pevion Biotech Ltd – Recent Pipeline Updates 23
Pevion Biotech Ltd - Dormant Projects 24
Pevion Biotech Ltd – Locations And Subsidiaries 25
Head Office 25
Pevion Biotech Ltd - Key Manufacturing Facilities 26
Recent Developments 27
Nov 11, 2010: Pevion Announces Positive Preliminary Results From Phase I Study Of PEV7 In Recurrent Vulvovaginal Candidiasis 27
Apr 23, 2010: Pevion Biotech Announces Encouraging Preclinical Results For PEV4 RSV Vaccine Candidate 27
Apr 23, 2010: Pevion Biotech Announces Encouraging Preclinical Results For PEV4 RSV Vaccine Candidate 28
Mar 23, 2010: Pevion Biotech's PEV7 Vulvovaginal Candidiasis Vaccine Enters Phase I 28
Jan 12, 2010: Novavax Announces Positive Preclinical Results For Respiratory Syncytial Virus (RSV) Vaccine Candidate 29
Jun 22, 2009: Positive Phase I Trial Results For Pevion Biotech’s And Bio Life Science’s Breast Cancer Vaccine 30
Jun 22, 2009: Positive Phase I Trial Results For Pevion Biotech’s And Bio Life Science’s Breast Cancer Vaccine 30
Mar 29, 2007: Pevion Biotech And Mymetics Enter Llicense Agreement. 31
Mar 29, 2007: Pevion Biotech And Mymetics Enter Llicense Agreement. 32
Dec 18, 2006: Hepatitis C Vaccine Enters Clinical Phase I 32
Financial Deals Landscape 33
Pevion Biotech Ltd, Deals Volume Summary, 2004 to YTD 2011 33
Pevion Biotech Ltd, Deals Summary By Region, 2004 to YTD 2011 34
Pevion Biotech Ltd, Deals Summary, 2004 to YTD 2011 35
Pevion Biotech Ltd Detailed Deal Summary 36
Asset Purchase 36
Mymetics Acquires Preventive Malaria Vaccine From Pevion Biotech 36
Acquisition 39
Crucell Completes Sale Of Its Stake In Pevion Biotech 39
Venture Financing 40
Pevion Biotech Secures $29 Million In Series A Financing